{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:09:33Z","timestamp":1761764973056},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,9,5]],"date-time":"2007-09-05T00:00:00Z","timestamp":1188950400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p><jats:bold>Objectives:\u2002<\/jats:bold> This pilot study evaluated the efficacy and safety of adjunctive topiramate compared with placebo in the treatment of patients with a diagnosis of schizoaffective disorder, bipolar type (SAD\u2010BT).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> A sample of 48 adult patients with a <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>, <jats:italic>4th Edition<\/jats:italic>, <jats:italic>Text Revision<\/jats:italic> (DSM\u2010IV\u2010TR) diagnosis of SAD\u2010BT (supported by the <jats:italic>Structured Clinical Interview for DSM\u2010IV Axis I Disorder<\/jats:italic>, <jats:italic>Patient Edition<\/jats:italic>) were randomly assigned in a 2:1 ratio (favoring topiramate) to 8\u2003weeks of double\u2010blind treatment with topiramate (100\u2013400\u2003mg\/day) or placebo. Patients who had achieved a \u226520% decrease from baseline in their Positive and Negative Syndrome Scale (PANSS) total scores were given the opportunity to continue for an additional 8\u2003weeks of double\u2010blind treatment. The dosage of the study medicine was continued unchanged from the earlier 8\u2010week study period. At the end of the study period, the study medicine was tapered and discontinued over a 2\u2010week period. Primary efficacy was assessed at 8\u2003weeks using the mean change between treatment groups of the PANSS total scores in the intent\u2010to\u2010treat population of randomized patients. Several secondary measures were also assessed. Safety analyses included monitoring of adverse events, vital signs, electrocardiogram (ECG) and laboratory values.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Even though both treatments reduced scores on various psychopathology rating scales, adjunctive topiramate treatment (nearly 275\u2003mg\/day) did not show increased efficacy relative to placebo on the primary outcome measure (PANSS scale) or any of the secondary outcome measures. Topiramate\u2010treated patients lost significantly more body weight than placebo\u2010treated patients, which led to a significant reduction in body mass index (BMI). Relative to adjunctive placebo, topiramate\u2010treated patients experienced higher rates of paresthesia, sedation, word\u2010finding difficulty, sleepiness, and forgetfulness, but these differences were not statistically significant. There were no clinically significant abnormalities in either the ECG or laboratory results. There were no serious adverse events in the study. Further, there was no worsening of the PANSS total scores (to \u226510% from baseline), and no significant differences between the treatments on worsening of total Montgomery\u2013Asberg Depression Rating Scale (MADRS) scores [1\/13 (7.7%) for placebo; 1\/25 (4.0%) for topiramate].<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> This pilot study did not support clinical efficacy for adjunctive topiramate treatment in patients with SAD\u2010BT. There were no major safety or tolerability issues in this study. Confirming the results of other studies, topiramate\u2010treated patients did experience greater body weight loss and reduction in BMI.<\/jats:p>","DOI":"10.1111\/j.1399-5618.2007.00506.x","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T04:59:37Z","timestamp":1189227577000},"page":"609-617","source":"Crossref","is-referenced-by-count":26,"title":["A placebo\u2010controlled, random\u2010assignment, parallel\u2010group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type"],"prefix":"10.1111","volume":"9","author":[{"given":"KN","family":"Roy Chengappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Kupfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haranath","family":"Parepally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineeth","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Buttenfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Schlicht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Houck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet S","family":"Brar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.1999.10111.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00316-9"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300023"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00524-9"},{"key":"e_1_2_6_6_2","first-page":"5","article-title":"Mechanism of action of newer anticonvulsants","volume":"64","author":"White HS.","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_7_2","first-page":"219","volume-title":"Bipolar Medications: Mechanisms of Action","author":"Post RM","year":"2000"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_6_9_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM\u2010IV\u2010TR","author":"American Psychiatric Association","year":"2000"},{"key":"e_1_2_6_10_2","volume-title":"Structured Clinical Interview for DSM\u2010IV Axis I Disorders \u2013 Patient Edition (SCID\u2010I\/P, Version 2.0)","author":"First MB","year":"1995"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_6_13_2","volume-title":"Clinical Global Impressions","author":"Guy W","year":"1976"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700050182"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"e_1_2_6_17_2","volume-title":"Abnormal Involuntary Movement Scale","author":"Guy W","year":"1976"},{"key":"e_1_2_6_18_2","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J.","year":"1988"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290040080014"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2006.00276.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200208000-00017"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00110-4"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2001.30501.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00126.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2005.00234.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802783"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.20305.x"},{"key":"e_1_2_6_28_2","first-page":"265","article-title":"Lithium combined with carbemazepine or haloperidol in the treatment of mania","volume":"31","author":"Small JG","year":"1995","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00115.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2007.00506.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2007.00506.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T22:14:02Z","timestamp":1696889642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2007.00506.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1399-5618.2007.00506.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2007.00506.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}